Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ-761 with Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer
NCT02514031Phase 1Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ARQ761 in pancreatic adenocarcinoma (PDAC), sponsored by UT Southwestern Medical Center. Primary endpoint: Maximum Tolerated Dose up to 8 months. Started Mar 2016; status: terminated.
02
Drugs
ARQ761
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02514031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514031.